Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleInduction of Angiogenesis in Microfluidics by using Prolyl Hydroxylase Inhibitor and Sphingosine I-Phosphate
dc.contributor.authorLIM SEI HIEN
dc.identifier.citationLIM SEI HIEN (2013-08-15). Induction of Angiogenesis in Microfluidics by using Prolyl Hydroxylase Inhibitor and Sphingosine I-Phosphate. ScholarBank@NUS Repository.
dc.description.abstractProlyl hydroxylase inhibitors (PHis) and sphigosine 1-phosphate (S1P) are shown to induce capillary sprouting in a co-culture microfluidic platform. Combining both factors further enhances the formation of complex tubular networks with lumina. The pro-angiogenic effects are only observed in co-culture with fibroblasts and are explained by the generation of mutually stimulating factors between endothelia (EC) and fibroblasts. S1P induced migration has been shown to be S1P receptor 1 (S1P1) dependent. The downregulation of either VEGF or S1P1 attenuates capillary sprouting and changes the sprouting morphologies. MCP-1 is mainly secreted by fibroblasts, but only in the presence of ECs or EC-conditioned medium, creating an angiogenic effect on sprouting. Blocking antibodies against MCP-1 inhibit the sprouting response. These observations not only confirm the importance of EC-fibroblast crosstalk in angiogenesis but also suggest that the combination of PHi and S1P enhances this synergy and thus might be of therapeutic value for tissue regeneration.
dc.subjectCiclopirox olamine (CPX), fibroblasts, S1P1, cellular crosstalk, MCP-1, VEGF
dc.contributor.departmentBIOMEDICAL ENGINEERING
dc.contributor.supervisorRAGHUNATH, MICHAEL
dc.contributor.supervisorROGER KAMM, MIT
dc.description.degreeconferredDOCTOR OF PHILOSOPHY
Appears in Collections:Ph.D Theses (Open)

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
LimSH.pdf6.02 MBAdobe PDF



Page view(s)

checked on Nov 24, 2020


checked on Nov 24, 2020

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.